- Home
- API vs ESPR Comparison
API vs ESPR Comparison
Compare API & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- API
- ESPR
- Stock Information
- Founded
- API 2013
- ESPR 2008
- Country
- API United States
- ESPR United States
- Employees
- API N/A
- ESPR N/A
- Industry
- API Computer Software: Prepackaged Software
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- API Technology
- ESPR Health Care
- Exchange
- API Nasdaq
- ESPR Nasdaq
- Market Cap
- API 283.7M
- ESPR 305.0M
- IPO Year
- API 2020
- ESPR 2013
- Fundamental
- Price
- API $2.61
- ESPR $0.95
- Analyst Decision
- API Strong Buy
- ESPR Buy
- Analyst Count
- API 1
- ESPR 7
- Target Price
- API $6.00
- ESPR $6.07
- AVG Volume (30 Days)
- API 903.5K
- ESPR 5.5M
- Earning Date
- API 05-21-2025
- ESPR 05-06-2025
- Dividend Yield
- API N/A
- ESPR N/A
- EPS Growth
- API N/A
- ESPR N/A
- EPS
- API N/A
- ESPR N/A
- Revenue
- API $133,256,000.00
- ESPR $332,314,000.00
- Revenue This Year
- API $6.89
- ESPR $5.17
- Revenue Next Year
- API $10.96
- ESPR N/A
- P/E Ratio
- API N/A
- ESPR N/A
- Revenue Growth
- API N/A
- ESPR 185.66
- 52 Week Low
- API $1.65
- ESPR $0.93
- 52 Week High
- API $6.99
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- API 22.97
- ESPR 22.73
- Support Level
- API $2.86
- ESPR $0.93
- Resistance Level
- API $3.21
- ESPR $1.06
- Average True Range (ATR)
- API 0.28
- ESPR 0.09
- MACD
- API -0.05
- ESPR -0.02
- Stochastic Oscillator
- API 5.07
- ESPR 3.57
About API Agora Inc.
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.